Pharmaceutical News

RSS

Study shows differences in rates of paracetamol-linked acute liver failure among European countries

A fifty-fold between-country difference in rates of paracetamol-induced acute liver failure that leads to liver transplant (ALFT) has been revealed by a study that compared patient data from seven countries at the request of the European Medicines Agency: France, Greece, Ireland, Italy, Netherlands, Portugal and the UK.

29 May 2015

DigiPath, Euphoria partner to set highest medical marijuana patient safety and education standards

DigiPath Labs of Las Vegas, a subsidiary of DigiPath, Inc., has entered into a one-year agreement with Euphoria Wellness to conduct comprehensive safety and potency tests on the products Euphoria will sell in its Las Vegas medical marijuana dispensary.

28 May 2015

Clinical trial suggests HIV patients should start therapy sooner rather than later

Findings from a large-scale clinical trial have shown that people with HIV should start antiretroviral therapy as soon as they have been diagnosed, irrespective of what their CD4+ count is...

28 May 2015

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Actavis plc announced today that VIBERZI (eluxadoline) was approved by the Food and Drug Administration as a twice-daily, oral treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed opioid receptor activity, it is a mu receptor agonist, a delta receptor antagonist, and a kappa receptor agonist.

28 May 2015

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration for Xifaxan 550 mg for the treatment of IBS-D in adults.

28 May 2015

Helsinn Group announces European approval of ALOXI (palonosetron HCl) injection for paediatric use

Helsinn Group, the Swiss Group focused on building quality cancer care, today announces that the European Commission has endorsed the Committee for Medicinal Products for Human Use's Opinion recommending the approval of ALOXI (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, in paediatric patients one month of age and older.

27 May 2015

HUYA Bioscience International named winner of bronze Stevie Award

HUYA Bioscience International has been named the winner of a bronze Stevie Award in the Health Products & Services and Pharmaceuticals category in the second annual Asia-Pacific Stevie Awards.

26 May 2015

UC Davis researchers show feasibility of using statins to treat asthma

Statins continue to show that their benefits extend beyond their original focus of lowering high cholesterol. With the increasing prevalence of asthma, scientists are studying the effects of statins in the lungs.

26 May 2015

High Grade Agarose for Nucleic Acid Electrophoresis

CleverGEL is a new environmentally friendly agarose suitable for routine analysis of nucleic acids using standard electrophoretic procedures...

25 May 2015

Researchers create new vaccine development method for H5N1, H7N9 strains of avian influenza

A recent study with Kansas State University researchers details vaccine development for two new strains of avian influenza that can be transmitted from poultry to humans. The strains have led to the culling of millions of commercial chickens and turkeys as well as the death of hundreds of people.

24 May 2015

Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Today, Rhodes Pharmaceuticals L.P. announced that Aptensio XR, a once-daily central nervous system stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will be available to patients beginning Summer 2015.

22 May 2015

Merus Labs International acquires rights to manufacture, market specialty pharmaceutical products in multiple countries

Merus Labs International Inc. is pleased to announce that one of its wholly owned subsidiaries has signed a definitive agreement to acquire the rights to manufacture, market, and sell two established specialty pharmaceutical products in certain European and other markets.

22 May 2015

Chemical compound shows promise in treating rheumatoid arthritis

Montana State University researchers and their collaborators have published their findings about a chemical compound that shows potential for treating rheumatoid arthritis.

22 May 2015

Existing anti-stroke drug can be effective in treating middle-ear infections

An existing anti-stroke drug is an effective treatment for middle-ear infections, showing the ability to suppress mucus overproduction, improve bacterial clearance and reduce hearing loss, according to researchers at Georgia State University and the University of Rochester.

21 May 2015

ICS use may lower risk of mortality from pneumonia and other causes in COPD patients

Treatment of COPD with inhaled corticosteroids (ICS) may decrease the risk of dying from pneumonia and from other causes despite being associated with an increase in the occurrence of pneumonia, according to a new meta-analysis presented at the 2015 American Thoracic Society International Conference.

21 May 2015

Canada lagging behind similar OECD countries with regard to public drug plan reimbursement

Canadians face wait times of over 460 days in order to get access to new, potentially lifesaving medicines in public drug plans, according to a new IMS Brogan report commissioned by Rx&D. Overall, the report ranks Canada 16 out of 18 similar OECD countries.

21 May 2015

FDA accepts Tris Pharma's Dyanavel XR NDA for review

Tris Pharma, Inc. announced that U.S. Food and Drug Administration has accepted for review its New Drug Application ("NDA") for Dyanavel XR (amphetamine) CII, an Extended-Release Oral Suspension.

21 May 2015

Enterprise Therapeutics secures additional funding to accelerate drug discovery for treatment of respiratory diseases

ENTERPRISE THERAPEUTICS Ltd, a drug discovery company focused on new therapeutics for respiratory diseases, today announced that it has secured an additional £2.4m ($3.6m) in Series-A financing.

21 May 2015

Second-generation antibiotic shows promise against common bacterial infections

Researchers led by St. Jude Children's Research Hospital scientists have developed a second-generation antibiotic that shows early effectiveness against common bacterial infections that pose a serious health threat to children and adults.

21 May 2015

HQO report shows variations across Ontario's long-term care homes regarding antipsychotic drug use

There are major differences across Ontario's long-term care homes in the percentage of residents who are being prescribed antipsychotic medications, according to Looking for Balance, a report from Health Quality Ontario, the provincial advisor on health care quality.

20 May 2015

Pharmaceutical News

Study shows differences in rates of paracetamol-linked acute liver failure among European countries

DigiPath, Euphoria partner to set highest medical marijuana patient safety and education standards

Clinical trial suggests HIV patients should start therapy sooner rather than later

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Helsinn Group announces European approval of ALOXI (palonosetron HCl) injection for paediatric use

HUYA Bioscience International named winner of bronze Stevie Award

UC Davis researchers show feasibility of using statins to treat asthma

High Grade Agarose for Nucleic Acid Electrophoresis

Researchers create new vaccine development method for H5N1, H7N9 strains of avian influenza

Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Merus Labs International acquires rights to manufacture, market specialty pharmaceutical products in multiple countries

Chemical compound shows promise in treating rheumatoid arthritis

Existing anti-stroke drug can be effective in treating middle-ear infections

ICS use may lower risk of mortality from pneumonia and other causes in COPD patients

Canada lagging behind similar OECD countries with regard to public drug plan reimbursement

FDA accepts Tris Pharma's Dyanavel XR NDA for review

Enterprise Therapeutics secures additional funding to accelerate drug discovery for treatment of respiratory diseases

Second-generation antibiotic shows promise against common bacterial infections

HQO report shows variations across Ontario's long-term care homes regarding antipsychotic drug use

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News